Oscar Health
OSCR
$28.26
-2.25%
Oscar Health, Inc. is a technology-driven health insurance company that offers Individual & Family plans and health technology solutions, primarily through the federal and state-run Affordable Care Act (ACA) exchanges. The company positions itself as a disruptor in the managed care industry, leveraging its proprietary full-stack technology platform to improve member engagement and streamline healthcare administration. The current investor narrative is focused on the company's path to sustainable profitability following a significant stock price recovery, driven by improved operational efficiency, member growth, and a favorable regulatory environment, including recent positive news regarding Medicare Advantage payment rates.…
OSCR
Oscar Health
$28.26
Related headlines
Investment Opinion: Should I buy OSCR Today?
Rating & Thesis: Hold. OSCR presents a high-risk, high-potential-reward speculative opportunity, but the severe profitability challenges and extreme volatility warrant caution until there is clearer evidence of a sustainable turnaround. The mixed and limited analyst sentiment, with recent actions ranging from Underweight to Overweight, underscores the high uncertainty.
Supporting Evidence: The primary valuation metric, a trailing PS ratio of 0.32x, suggests the stock is deeply undervalued relative to its revenue, trading near its historical lows. Revenue growth remains robust at 17.25% YoY, and the company generated substantial TTM free cash flow of $1.06 billion. However, these positives are counterbalanced by a catastrophic decline in gross margin to 6.6% and a net loss margin of -12.6% in Q4 2025. The stock's 2.34 beta confirms its status as a highly volatile, speculative holding.
Risks & Conditions: The two biggest risks are the continued deterioration of gross margins and the stock's vulnerability to a sharp reversal given its parabolic recent move. This Hold rating would upgrade to a Buy if the company demonstrates two consecutive quarters of gross margin stabilization/expansion above 10% and provides clear guidance toward net profitability. It would downgrade to a Sell if QoQ revenue growth turns negative or if the gross margin falls below 5%. Relative to its history and the severe fundamental challenges, the stock appears fairly valued at its current distressed sales multiple, but not yet undervalued enough to offset the binary risk profile.
Sign up to view all
OSCR 12-Month Price Forecast
The outlook for OSCR is bifurcated and hinges almost entirely on the trajectory of its gross margin. The recent powerful rally is more reflective of technical momentum and sector tailwinds than a fundamental improvement, as profitability metrics have sharply deteriorated. The neutral stance reflects a 50% probability for a base case of volatile consolidation, with equal 25% weights on a bullish re-rating or a bearish collapse. The stance would upgrade to bullish on evidence of sustained gross margin recovery above 10% for two consecutive quarters. It would downgrade to bearish if margins fall further or if revenue growth decelerates below 10% YoY. Investors should view this as a speculative trading vehicle, not a fundamental long-term investment at this stage.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Oscar Health's 12-month outlook, with a consensus price target around $36.74 and implied upside of +30.0% versus the current price.
Average Target
$36.74
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$23 - $37
Analyst target range
Analyst coverage for Oscar Health is limited, with only 3 analysts providing estimates, indicating this is a stock with less institutional research scrutiny which can contribute to higher volatility. The consensus sentiment is difficult to gauge precisely without explicit Buy/Hold/Sell ratings and price targets in the provided data, but the available institutional ratings show a mixed and cautious picture, with recent actions including an upgrade to Overweight by Piper Sandler and a downgrade to Neutral by Baird in mid-2025. The wide range of analyst actions—from Underweight (Wells Fargo, Barclays) to Overweight (Piper Sandler)—signals high uncertainty and a lack of consensus on the company's outlook. The implied upside or downside to a consensus target cannot be calculated due to missing data, but the limited coverage and divergent ratings themselves are a key signal, often associated with small to mid-cap companies or those undergoing a business model transition, where future outcomes are highly debated.
Bulls vs Bears: OSCR Investment Factors
The investment debate for OSCR is a classic battle between deep value and fundamental risk. The bull case, currently supported by powerful technical momentum, is anchored in extreme undervaluation (0.32x PS), strong revenue growth, and a favorable sector catalyst. The bear case is grounded in a severe and deteriorating profitability profile, with gross margins collapsing to 6.6% and net losses persisting. Currently, the technical momentum and valuation discount provide stronger near-term evidence for the bulls, but this is a highly speculative bet on a future turnaround. The single most important tension is the resolution of the profitability crisis. If OSCR can stabilize and expand its gross margins while continuing to grow revenue, the stock could re-rate significantly. If losses persist or widen, the current low valuation may be justified, and the recent rally could prove unsustainable.
Bullish
- Extreme Undervaluation on Revenue: The stock trades at a trailing Price-to-Sales (PS) ratio of 0.32x, which is near the absolute bottom of its historical range and represents a deep discount to its revenue base. This valuation implies the market has priced in significant skepticism, leaving substantial room for multiple expansion if the company's profitability narrative improves.
- Powerful Technical Momentum and Breakout: OSCR has surged 70.52% over the past three months and 66.78% over the past year, dramatically outperforming the SPY. The stock has broken out from a low near $10.85 and is now trading at 92% of its 52-week high ($25.58), indicating strong bullish momentum and a potential regime change from its previous downtrend.
- Strong Revenue Growth Trajectory: The company delivered 17.25% year-over-year revenue growth in Q4 2025, reaching $2.81 billion. This robust top-line expansion demonstrates continued market penetration and member growth, which is critical for a growth-stage insurer scaling its platform.
- Positive Regulatory Catalyst for Sector: Recent news highlights a larger-than-expected 2027 Medicare Advantage payment increase from CMS, which has boosted sentiment across the managed care sector. This favorable regulatory backdrop reduces a key uncertainty for health insurers and could improve Oscar's future revenue visibility.
Bearish
- Severe and Worsening Profitability Crisis: OSCR posted a net loss of $352.6 million in Q4 2025, and its gross margin collapsed to 6.6% from 25.8% in Q1 2025. This dramatic margin compression, coupled with a deeply negative Return on Equity (-45.33%), signals severe underlying pressure on medical costs and underwriting profitability.
- Extreme Stock Price Volatility: With a beta of 2.34, OSCR's stock is more than twice as volatile as the broader market. This is evidenced by a maximum drawdown of -51.71% in the provided data, indicating high risk for investors and potential for sharp declines even amidst a strong uptrend.
- Liquidity and Solvency Concerns: The company's current ratio is 0.95, indicating current liabilities slightly exceed current assets, which could signal near-term liquidity constraints. While debt-to-equity of 0.44 is moderate, the combination with persistent losses raises solvency questions if the path to profitability is delayed.
- High Short Interest and Analyst Skepticism: A short ratio of 2.38 indicates significant bearish sentiment from short sellers. Furthermore, analyst coverage is limited and mixed, with recent actions including downgrades to Neutral and Underweight, reflecting high uncertainty and a lack of consensus on the company's future.
OSCR Technical Analysis
The stock is in a powerful and sustained uptrend, having gained 66.78% over the past year, significantly outperforming the SPY's 27.04% return. As of the latest close at $23.60, the price is trading at approximately 92% of its 52-week high of $25.58, indicating strong momentum and proximity to recent highs, which suggests bullish sentiment but also raises the risk of a near-term pullback. The stock has surged 31.55% over the past month and 70.52% over the past three months, demonstrating accelerating momentum that far exceeds the broader market's gains of 4.6% and 12.6%, respectively, over the same periods. This recent parabolic move, especially from a low near $10.85 in late March 2026, suggests a powerful breakout from a previous downtrend, though such rapid appreciation can lead to overbought conditions and increased volatility. Key technical support is at the 52-week low of $10.69, while immediate resistance is at the 52-week high of $25.58; a decisive breakout above $25.58 would confirm the strength of the uptrend, while a failure could signal a consolidation phase. With a beta of 2.34, Oscar Health's stock is more than twice as volatile as the market, which is critical for risk management as it implies larger swings in both directions, as evidenced by the 51.71% maximum drawdown in the provided data.
Beta
2.39
2.39x market volatility
Max Drawdown
-51.7%
Largest decline past year
52-Week Range
$11-$29
Price range past year
Annual Return
+97.1%
Cumulative gain past year
| Period | OSCR Return | S&P 500 |
|---|---|---|
| 1m | +19.6% | -0.1% |
| 3m | +113.6% | +12.0% |
| 6m | +69.9% | +8.8% |
| 1y | +97.1% | +22.9% |
| ytd | +88.8% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
OSCR Fundamental Analysis
Revenue growth remains robust, with the most recent quarterly revenue of $2.81 billion representing a 17.25% year-over-year increase; however, examining the quarterly income statements reveals significant volatility, with revenue peaking at $3.05 billion in Q1 2025 before declining sequentially to $2.81 billion in Q4 2025, indicating potential seasonality or growth normalization. The company is not yet consistently profitable, posting a net loss of $352.6 million in Q4 2025, though this is an improvement from a net loss of $153.5 million in Q4 2024; the gross margin of 6.6% in the latest quarter is notably low and has compressed from 13.4% in Q3 2025 and 25.8% in Q1 2025, highlighting significant pressure on underwriting profitability or medical cost ratios. The balance sheet shows a debt-to-equity ratio of 0.44, indicating moderate leverage, and a current ratio of 0.95 suggests potential liquidity constraints with current liabilities slightly exceeding current assets. Positively, the company generated substantial free cash flow of $1.06 billion on a trailing twelve-month basis, and its return on equity is deeply negative at -45.33%, underscoring the ongoing challenge of translating top-line growth into shareholder returns.
Quarterly Revenue
$2.8B
2025-12
Revenue YoY Growth
+0.17%
YoY Comparison
Gross Margin
+0.06%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is OSCR Overvalued?
Given the company's negative net income, we lead with the Price-to-Sales (PS) ratio for valuation. Oscar Health's trailing PS ratio is 0.32, which is exceptionally low and suggests the market is valuing the company at a deep discount to its revenue base, likely due to persistent losses. There is no forward PS ratio provided for a direct comparison, but the low trailing multiple reflects skepticism about near-term profitability. A direct peer comparison using industry averages is not available in the provided data, but the sub-0.5x sales multiple is typically associated with companies facing significant fundamental challenges or operating in highly competitive, low-margin industries. Historically, the stock's own PS ratio has fluctuated significantly, ranging from a high above 13x in early 2021 post-IPO to the current 0.32x; the current multiple is near the absolute bottom of its historical range, which could signal either a deep value opportunity if the profitability trajectory improves or a justified discount if losses persist.
PE
-8.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -28x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-3.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Oscar Health faces acute financial risks centered on its inability to achieve consistent profitability. The company's gross margin collapsed from 25.8% in Q1 2025 to just 6.6% in Q4 2025, indicating severe pressure from medical costs that threatens its business model. With a net loss of $352.6 million in the latest quarter and a deeply negative ROE of -45.33%, the company remains dependent on external capital and growth to justify its existence. Furthermore, a current ratio of 0.95 suggests potential liquidity constraints, as current liabilities slightly exceed current assets, raising concerns about its ability to manage short-term obligations without additional financing.
Market & Competitive Risks: The primary market risk is valuation compression if the profitability narrative fails to materialize. While the stock trades at a deeply discounted 0.32x sales, this multiple could contract further if losses persist, as the market may assign a 'value trap' label. Competitive risks are high in the crowded, low-margin ACA exchange market dominated by larger, profitable insurers. The stock's beta of 2.34 makes it highly sensitive to broader market swings, and its recent parabolic 70% 3-month gain increases the risk of a sharp pullback on any negative news or sector rotation away from speculative growth stories.
Worst-Case Scenario: The worst-case scenario involves a continuation of the gross margin collapse, leading to larger-than-expected quarterly losses that deplete cash reserves and force a dilutive capital raise. This could trigger analyst downgrades, a loss of investor confidence, and a rapid unwinding of the recent momentum trade. In this adverse scenario, the stock could realistically retrace to its 52-week low of $10.69, representing a downside of approximately -55% from the current price of $23.60. Given the stock's history of a -51.71% maximum drawdown, such a decline is within the realm of historical volatility for this name.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: The gross margin collapse from 25.8% to 6.6% in 2025 indicates a severe underlying issue with medical costs that threatens the business model. 2) Volatility Risk: With a beta of 2.34, the stock is prone to extreme swings, as seen in its 51.71% max drawdown and recent 70% 3-month surge. 3) Liquidity/Solvency Risk: A current ratio of 0.95 shows potential near-term liquidity constraints. 4) Sentiment Risk: High short interest (short ratio 2.38) and mixed analyst ratings create a fragile sentiment backdrop where negative news could trigger a sharp sell-off.
The 12-month forecast is highly uncertain, with three distinct scenarios. The Base Case (50% probability) sees the stock consolidating between $20 and $25, as choppy fundamentals lead to volatile trading. The Bull Case (25% probability), targeting $30-$35, requires a clear profitability turnaround and sustained breakout above $25.58. The Bear Case (25% probability), targeting $10-$15, involves further margin deterioration and a full retracement of the recent rally. The most likely outcome is the base case of high volatility within a range, as the market awaits clearer evidence on the profitability front.
OSCR is deeply undervalued on a revenue basis but may be fairly or overvalued given its fundamental challenges. Its trailing Price-to-Sales ratio of 0.32x is near the bottom of its historical range and suggests the market is pricing in significant distress. However, this low multiple is justified by persistent net losses (-$352.6M in Q4 2025) and a collapsing gross margin. The valuation implies the market expects either a turnaround or continued deterioration. Compared to profitable peers, it trades at a discount, but that discount reflects its higher risk profile rather than a clear margin of safety.
OSCR is a speculative, high-risk/high-reward proposition, not a 'good buy' for most investors. For aggressive traders comfortable with volatility (beta of 2.34), the deep valuation discount at 0.32x sales and powerful technical momentum offer a compelling trade. However, the severe and worsening profitability crisis, with gross margins collapsing to 6.6%, makes it a poor choice for long-term, fundamentals-driven investors. A purchase here is a bet that the company can fix its margins; without that, the recent rally could fully reverse toward the 52-week low of $10.69.
OSCR is unsuitable for a traditional long-term 'buy and hold' investment given its lack of profitability and extreme volatility. It is best approached as a short-to-medium-term tactical trade by investors who can actively monitor its quarterly fundamentals and technical levels. The high beta of 2.34 and binary outlook based on margin trends make it a trading vehicle rather than a core holding. A suggested minimum holding period does not apply; this is a position that should be reevaluated after each earnings report. Only if the company demonstrates a clear, multi-quarter path to profitability would it become a candidate for a longer-term growth investment.